JP2004509645A - 方法 - Google Patents
方法 Download PDFInfo
- Publication number
- JP2004509645A JP2004509645A JP2002530855A JP2002530855A JP2004509645A JP 2004509645 A JP2004509645 A JP 2004509645A JP 2002530855 A JP2002530855 A JP 2002530855A JP 2002530855 A JP2002530855 A JP 2002530855A JP 2004509645 A JP2004509645 A JP 2004509645A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- proteins
- array
- tag
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 120
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 201
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 169
- 238000012216 screening Methods 0.000 claims abstract description 21
- 239000003550 marker Substances 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 235000018102 proteins Nutrition 0.000 claims description 157
- 108020004414 DNA Proteins 0.000 claims description 41
- 230000003993 interaction Effects 0.000 claims description 32
- 239000002299 complementary DNA Substances 0.000 claims description 27
- 108010026552 Proteome Proteins 0.000 claims description 24
- 238000012217 deletion Methods 0.000 claims description 24
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims description 22
- 230000037430 deletion Effects 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 21
- 108020004705 Codon Proteins 0.000 claims description 20
- 238000010367 cloning Methods 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 238000009739 binding Methods 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000003498 protein array Methods 0.000 claims description 19
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 18
- 230000004850 protein–protein interaction Effects 0.000 claims description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 15
- 101710163270 Nuclease Proteins 0.000 claims description 14
- 239000005090 green fluorescent protein Substances 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 13
- 230000029087 digestion Effects 0.000 claims description 13
- 108010052305 exodeoxyribonuclease III Proteins 0.000 claims description 12
- 108060002716 Exonuclease Proteins 0.000 claims description 9
- 102000013165 exonuclease Human genes 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 108700026244 Open Reading Frames Proteins 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 6
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 6
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
- 108091026890 Coding region Proteins 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010086093 Mung Bean Nuclease Proteins 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 102000006240 membrane receptors Human genes 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 4
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 238000002493 microarray Methods 0.000 claims description 4
- 108010037497 3'-nucleotidase Proteins 0.000 claims description 3
- 238000001261 affinity purification Methods 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 235000004252 protein component Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 108010006785 Taq Polymerase Proteins 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 230000001915 proofreading effect Effects 0.000 claims 1
- 238000010839 reverse transcription Methods 0.000 claims 1
- 238000003491 array Methods 0.000 abstract description 17
- 102000005720 Glutathione transferase Human genes 0.000 description 33
- 108010070675 Glutathione transferase Proteins 0.000 description 33
- 239000013598 vector Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 230000004927 fusion Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 12
- 239000006166 lysate Substances 0.000 description 12
- 102000003945 NF-kappa B Human genes 0.000 description 11
- 150000002611 lead compounds Chemical class 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 101150066516 GST gene Proteins 0.000 description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 9
- 230000004568 DNA-binding Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 108091081024 Start codon Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010058683 Immobilized Proteins Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010010677 Phosphodiesterase I Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091006054 His-tagged proteins Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
- 229960003669 carbenicillin Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 108010052780 polyasparagine Proteins 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101000997963 Aequorea victoria Green fluorescent protein Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010041525 Alanine racemase Proteins 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101150099894 GDHA gene Proteins 0.000 description 1
- 238000010631 GST assay Methods 0.000 description 1
- 101000928753 Homo sapiens 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 1
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 108010019653 Pwo polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000043371 human FGL1 Human genes 0.000 description 1
- 102000056093 human HSD11B1 Human genes 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0020357A GB0020357D0 (en) | 2000-08-17 | 2000-08-17 | Method |
| US24799500P | 2000-11-14 | 2000-11-14 | |
| PCT/GB2001/003693 WO2002027327A2 (en) | 2000-08-17 | 2001-08-17 | Rapid profiling of the interactions between a chemical entity and proteins in a given proteome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004509645A true JP2004509645A (ja) | 2004-04-02 |
| JP2004509645A5 JP2004509645A5 (enExample) | 2008-10-02 |
Family
ID=26244855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002530855A Pending JP2004509645A (ja) | 2000-08-17 | 2001-08-17 | 方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1326970A2 (enExample) |
| JP (1) | JP2004509645A (enExample) |
| KR (1) | KR20030043933A (enExample) |
| CN (1) | CN1494589A (enExample) |
| AU (1) | AU2001279948A1 (enExample) |
| BR (1) | BR0113330A (enExample) |
| CA (1) | CA2420415A1 (enExample) |
| GB (1) | GB2384779B (enExample) |
| IL (1) | IL154486A0 (enExample) |
| WO (1) | WO2002027327A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012154938A (ja) * | 2004-09-22 | 2012-08-16 | Odyssey Thera Inc | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202018D0 (en) | 2002-01-29 | 2002-03-13 | Sense Proteomic Ltd | Tag and method |
| DK1565754T3 (da) * | 2002-10-25 | 2007-12-17 | Sense Proteomic Ltd | Nye anvendelser af proteiner der kodes for af BLE generne og antibiotika fra bleomycinfamilien |
| GB2460717A (en) | 2008-06-11 | 2009-12-16 | Sense Proteomic Ltd | Autoantibodies for the detection of a predisposition to Lupus |
| GB2478734A (en) | 2010-03-15 | 2011-09-21 | Sense Proteomic Ltd | Auto-antibody biomarkers of prostate cancer |
| GB201017520D0 (en) | 2010-10-15 | 2010-12-01 | Sense Proteomic Ltd | Biomarkers |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999039210A1 (en) * | 1998-01-29 | 1999-08-05 | Miller, Samuel | High density arrays for proteome analysis and methods and compositions therefor |
| WO2000004382A1 (en) * | 1998-07-14 | 2000-01-27 | Zyomyx, Inc. | Arrays of proteins and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011777A1 (en) * | 1997-09-03 | 1999-03-11 | Biovation Limited | Methods for protein screening |
| CA2323638A1 (en) * | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| DE69933679T2 (de) * | 1998-08-12 | 2007-08-23 | Zycos Inc., Cambridge | Darstellung des profils und katalogisierung von exprimierten proteinmarkern |
| CA2372795A1 (en) * | 1999-07-12 | 2001-01-18 | Robert G. Kuimelis | C-terminal protein tagging |
| EP1203238B1 (en) * | 2000-01-31 | 2010-08-11 | Sense Proteomic Limited | Methods of generating protein expression arrays and the use thereof in rapid screening |
-
2001
- 2001-08-17 IL IL15448601A patent/IL154486A0/xx unknown
- 2001-08-17 JP JP2002530855A patent/JP2004509645A/ja active Pending
- 2001-08-17 BR BR0113330-6A patent/BR0113330A/pt not_active IP Right Cessation
- 2001-08-17 KR KR10-2003-7002339A patent/KR20030043933A/ko not_active Withdrawn
- 2001-08-17 WO PCT/GB2001/003693 patent/WO2002027327A2/en not_active Ceased
- 2001-08-17 AU AU2001279948A patent/AU2001279948A1/en not_active Abandoned
- 2001-08-17 CA CA002420415A patent/CA2420415A1/en not_active Abandoned
- 2001-08-17 EP EP01958221A patent/EP1326970A2/en not_active Withdrawn
- 2001-08-17 GB GB0306057A patent/GB2384779B/en not_active Expired - Fee Related
- 2001-08-17 CN CNA018157068A patent/CN1494589A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999039210A1 (en) * | 1998-01-29 | 1999-08-05 | Miller, Samuel | High density arrays for proteome analysis and methods and compositions therefor |
| WO2000004382A1 (en) * | 1998-07-14 | 2000-01-27 | Zyomyx, Inc. | Arrays of proteins and methods of use thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012154938A (ja) * | 2004-09-22 | 2012-08-16 | Odyssey Thera Inc | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030043933A (ko) | 2003-06-02 |
| WO2002027327A2 (en) | 2002-04-04 |
| IL154486A0 (en) | 2003-09-17 |
| CA2420415A1 (en) | 2002-04-04 |
| GB2384779B (en) | 2004-09-29 |
| GB0306057D0 (en) | 2003-04-23 |
| EP1326970A2 (en) | 2003-07-16 |
| AU2001279948A1 (en) | 2002-04-08 |
| BR0113330A (pt) | 2003-12-30 |
| GB2384779A (en) | 2003-08-06 |
| WO2002027327A3 (en) | 2003-04-17 |
| CN1494589A (zh) | 2004-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7094568B2 (en) | Method for producing proteins tagged at the N- or C-terminus | |
| AU773236B2 (en) | Selection of proteins using RNA-protein fusions | |
| US8207093B2 (en) | Selection of proteins using RNA-protein fusions | |
| US5723584A (en) | Biotinylation of proteins | |
| EP0833941B1 (en) | Polypeptides having a functional domain of interest and methods of identifying and using same | |
| EP1203238B1 (en) | Methods of generating protein expression arrays and the use thereof in rapid screening | |
| JP2008173124A (ja) | Ｗｗドメインを有する新規ポリペプチドの同定と単離およびその利用方法 | |
| US7816098B2 (en) | Methods of making and using a protein array | |
| EP1565754B1 (en) | New uses of proteins encoded by ble genes and antibiotics from the bleomycin family | |
| JP4303112B2 (ja) | 可溶性蛋白質ドメインの生成及び同定のための方法 | |
| JP2004509645A (ja) | 方法 | |
| JP4730804B2 (ja) | 方法 | |
| US20040253578A1 (en) | Dynamic action reference tools | |
| US20030091999A1 (en) | Compositions and methods for identifying polypeptides and nucleic acid molecules | |
| CA2462732A1 (en) | Target assisted iterative screening (tais) : a novel screening format for large molecular repertoires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080818 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110517 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110811 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110818 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110915 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110926 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120328 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120404 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120911 |